• Active-Life: 4-6 hours
  • Drug Class: Aromatase inhibitor (Oral)
  • Average Reported Dosage: 0.5-3.0 mg daily
  • Acne: No
  • Water Retention: None
  • Liver Toxic: Yes dosage dependent
  • Decreases HPTA function: Increases it.
Arimidex is an aromatase inhibitor (sometimes called an AI). It is usually provided in 1MG tabs or in liquid form. The drug works in a non-steroid form by inhibiting the aromatase enzyme which convertstestosterone and other androgens into estrogen. This means that there is less estrogen tocause female pattern fat deposits, gyno, and water retention. In medicine, Arimidex isutilized to treat prostate cancer. In sports chemistry, the drug has been employed as ameans of preventing excessive estrogenic side effects during AAS use and to aid increating a harder appearing musculature for competitive bodybuilders. Unlike Nolvadex,which simply block estrogen receptor-sites, this drug prevents or reduces estrogenproduction. Though some estrogen presence is noted as necessary for AAS to reach fulleffectiveness, too much can cause a layer of fat, water retention, and breast tissue growthpotentially with tumors called gynecomastia or bitch tits. Arimidex has a 75-85%aromatization inhibition rate.
Males who experienced excessive aromatization of AAS or who were extremelyestrogen sensitive usually utilized a dosage of 0.5-3.0 mg daily. In fact, most realizedexcellent estrogen control with only 0.5mg/d (mg daily). Women usually showedexcellent lean appearances (even in their legs) with 0.5-1.0 mg daily. Arimidex has a veryshort active-life so 0.5 mg dosages were often taken 2-6 times daily at equal intervals.Stacking 10-30 mg of Nolvadex with 1.0 mg of Arimidex has resulted in a near "0"estrogen activity situation regardless of the AAS protocol utilized. Directly following anAAS cycle, estrogen control has also become a problem (during periods intended for reestablishingHPTA function). In this case, the dosage was reduced from a higher startingdosage to a low dosage that was continued for 7-14 days after AAS discontinuance. Thisprotocol was considered necessary to assure clearing of AAS induced estrogen build-up.